Search - tctmd.com

Displaying 101 - 120 of 238

Sort: Relevancy | Date

News Daily News

New Absorb BVS Meta-analysis Begs the Question: When to Stop Studying a First-Gen Device?

Shelley Wood

July 21, 2017

News Conference News EuroPCR 2017

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

Michael O'Riordan

May 15, 2017

News Conference News ACC 2017

TAVR for Bicuspid Aortic Stenosis? Registry Offers Clues to Safety, Outcomes

Shelley Wood

March 24, 2017

News Daily News

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

Michael O'Riordan

February 02, 2017

Presentation TCT 2016

Trial #9 - The Essentials ofIN.PACT SFA: 3-year Outcomes of a Paclitaxel-Coated Balloon for Femoropopliteal Lesions

Presenter: William A. Gray, Stephan Windecker, John R. Laird Jr.

October 31, 2016

Presentation TCT 2016

ACT I Critique: Pro and Con

Presenter: William A. Gray, Stephan Windecker, Klaus D. Mathias

October 31, 2016

Presentation TCT 2016

Trial #8 - The Essentials ofThe ACT I Trial: Carotid Stenting vs Surgery In Asymptomatic Patients

Presenter: William A. Gray, Stephan Windecker, Kenneth Rosenfield

October 31, 2016

Presentation TCT 2016

CTSN Severe MR 2-Year Critique: Pro and Con

Presenter: William A. Gray, Stephan Windecker, Patrick M. McCarthy

October 31, 2016

Presentation TCT 2016

Trial #7 - The Essentials ofCTSN SMR Trial - Two-Year Outcomes Following Mitral Valve Repair or Replacement for Severe Ischemic Mitral Regurgitation

Presenter: William A. Gray, Stephan Windecker, Michael Argenziano

October 31, 2016

Presentation TCT 2016

PARTNER 2 and SAPIEN 3 Critique: Pros and Cons

Presenter: William A. Gray, Stephan Windecker

October 31, 2016

Presentation TCT 2016

Trial #6 - The Essentials ofPARTNER 2 and SAPIEN 3 - TAVR In Intermediate Risk Patients, and Improved TAVR Devices

Presenter: William A. Gray, Stephan Windecker, Vinod H. Thourani

October 31, 2016

Presentation TCT 2016

FORWARD: Multicenter, Prospective Registry Evaluating a Repositionable Self-Expanding Aortic Bioprosthesis in Patients with Severe Aortic Stenosis

Presenter: Thomas F. Luscher, Patrick W. Serruys, Stephan Windecker

October 31, 2016

Presentation TCT 2016

Debate: Bioabsorbable Polymer DES vs Durable Polymer DES -Second Generation Durable Polymer DES are the Gold Standard and Remain Superior to Bioabsorbable Polymer DES!

Presenter: Stephan Windecker, Tullio Palmerini

October 31, 2016

Presentation TCT 2016

Debate: Bioabsorbable Polymer DES vs Durable Polymer DES -Biodegradable Polymer DES will Replace Durable Polymer DES!

Presenter: Stephan Windecker, Michael Joner

October 31, 2016

Presentation TCT 2016

Featured Lecture: Overview of Currently Available and Under Development Bioabsorbable Polymer-based DES Programs. Are There Meaningful Differences?

Presenter: Stephan Windecker, Julinda Mehilli

October 31, 2016

Presentation TCT 2016

Potential Advantages and Pitfalls of Bioabsorbable Polymers

Presenter: Stephan Windecker, Renu Virmani

October 31, 2016

Presentation TCT 2016

Case Presentation: Evaluation and Management of Recurrent DES Restenosis

Presenter: Fernando Alfonso, Stephan Windecker, Adnan K. Chhatriwalla

October 30, 2016

Presentation TCT 2016

Is Brachytherapy the Best Last Hope for Recurrent DES Restenosis?

Presenter: Fernando Alfonso, Stephan Windecker, Ron Waksman

October 30, 2016

Presentation TCT 2016

Prognosis and Treatment Options for DES Restenosis and Re-restenosis

Presenter: Fernando Alfonso, Stephan Windecker

October 30, 2016

Presentation TCT 2016

Case Presentation: A Surprise in the Evaluation and Management of Stent Thrombosis

Presenter: Fernando Alfonso, Stephan Windecker, Ehrin J. Armstrong

October 30, 2016

Advertisement

New Absorb BVS Meta-analysis Begs the Question: When to Stop Studying a First-Gen Device?

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

TAVR for Bicuspid Aortic Stenosis? Registry Offers Clues to Safety, Outcomes

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

Trial #9 - The Essentials ofIN.PACT SFA: 3-year Outcomes of a Paclitaxel-Coated Balloon for Femoropopliteal Lesions

ACT I Critique: Pro and Con

Trial #8 - The Essentials ofThe ACT I Trial: Carotid Stenting vs Surgery In Asymptomatic Patients

CTSN Severe MR 2-Year Critique: Pro and Con

Trial #7 - The Essentials ofCTSN SMR Trial - Two-Year Outcomes Following Mitral Valve Repair or Replacement for Severe Ischemic Mitral Regurgitation

PARTNER 2 and SAPIEN 3 Critique: Pros and Cons

Trial #6 - The Essentials ofPARTNER 2 and SAPIEN 3 - TAVR In Intermediate Risk Patients, and Improved TAVR Devices

FORWARD: Multicenter, Prospective Registry Evaluating a Repositionable Self-Expanding Aortic Bioprosthesis in Patients with Severe Aortic Stenosis

Debate: Bioabsorbable Polymer DES vs Durable Polymer DES -Second Generation Durable Polymer DES are the Gold Standard and Remain Superior to Bioabsorbable Polymer DES!

Debate: Bioabsorbable Polymer DES vs Durable Polymer DES -Biodegradable Polymer DES will Replace Durable Polymer DES!

Featured Lecture: Overview of Currently Available and Under Development Bioabsorbable Polymer-based DES Programs. Are There Meaningful Differences?

Potential Advantages and Pitfalls of Bioabsorbable Polymers

Case Presentation: Evaluation and Management of Recurrent DES Restenosis

Is Brachytherapy the Best Last Hope for Recurrent DES Restenosis?

Prognosis and Treatment Options for DES Restenosis and Re-restenosis

Case Presentation: A Surprise in the Evaluation and Management of Stent Thrombosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content